PMID- 25872413
OWN - NLM
STAT- MEDLINE
DCOM- 20161027
LR  - 20181202
IS  - 1973-9478 (Electronic)
IS  - 1120-009X (Linking)
VI  - 27
IP  - 6
DP  - 2015
TI  - Severe and fatal adverse events risk associated with rituximab addition to B-cell 
      non-Hodgkin's lymphoma (B-NHL) chemotherapy: a meta-analysis.
PG  - 365-70
LID - 10.1179/1973947815Y.0000000025 [doi]
AB  - PURPOSE: Rituximab is a monoclonal antibody targetting the CD20 antigen with the 
      ability to increase overall remission (OR) in B-cell non-Hodgkin's lymphoma 
      (B-NHL). A systematic review and meta-analysis were conducted to determine the 
      risk of the most clinically relevant severe and fatal adverse events (AEs) 
      associated with the use of rituximab in the treatment of B-NHL. PATIENTS AND 
      METHODS: We included phase III clinical trials that used chemotherapy in 
      combination with rituximab or chemotherapy alone as for B-NHL. Statistical 
      analyses were conducted to calculate summary risk ratio (RR) of the relevant 
      severe and fatal AEs related with rituximab. RESULTS: Eight randomised controlled 
      clinical trials were included in this meta-analysis. Summary RR obtained showed 
      no statistically significant rituximab-associated increased risk in 13 severe 
      adverse events (SAEs) (infection, fever, anaemia, thrombocytopaenia, 
      granulocytopenia, liver toxicity, cardiac toxicity, neurologic toxicity, lung 
      toxicity, mucositis, nausea/vomiting, diarrhoea, alopecia) except leukocytopenia 
      (36.4% versus 31%; RR = 1.13; 95%CI, 1.01-1.27; P = 0.03). The incidences of 
      fatal AEs showed noteworthy difference between rituximab group and control group 
      (RR = 1.45; 95% CI, 1.04-2.02; P = 0.03). CONCLUSION: This meta-analysis 
      indicates that there was no proof of statistically higher incidence of most SAEs 
      in rituximab containing group compared with chemotherapy alone. However, fatal 
      infections were more frequently observed in patients who received rituximab. 
      Considering the low-incidence infection-induced death during the treatment 
      period, the effects of rituximab on infections need further investigation.
FAU - Hua, Qingling
AU  - Hua Q
AD  - Department of Oncology, The First Affiliated Hospital of Anhui Medical University 
      , Hefei, China.
FAU - Zhu, Yanzhe
AU  - Zhu Y
FAU - Liu, Hu
AU  - Liu H
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20150415
PL  - England
TA  - J Chemother
JT  - Journal of chemotherapy (Florence, Italy)
JID - 8907348
RN  - 0 (Antigens, CD20)
RN  - 0 (Antineoplastic Agents)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Antigens, CD20/immunology
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Clinical Trials, Phase III as Topic
MH  - Humans
MH  - Lymphoma, B-Cell/*drug therapy/mortality
MH  - Odds Ratio
MH  - Randomized Controlled Trials as Topic
MH  - Rituximab/*adverse effects/therapeutic use
OTO - NOTNLM
OT  - B-cell non-Hodgkin's lymphoma
OT  - Fatal adverse events
OT  - Rituximab
OT  - Severe adverse events
EDAT- 2015/04/16 06:00
MHDA- 2016/11/01 06:00
CRDT- 2015/04/16 06:00
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2016/11/01 06:00 [medline]
AID - 10.1179/1973947815Y.0000000025 [doi]
PST - ppublish
SO  - J Chemother. 2015;27(6):365-70. doi: 10.1179/1973947815Y.0000000025. Epub 2015 
      Apr 15.